NUVBEarnings•businesswire•
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Negative (30)
Summary
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “With FDA approval of IBTROZI, we’re proud of our swift evolution into a commercial‐stage company executing across functions to deliver a differentiated therapy to 70 patients in just seven weeks,” said David Hung, M.D., Founder, President, an
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by businesswire